New study shows ivermectin shrinks brain tumours by 70%
By Rhoda Wilson on October 23, 2025
Glioblastoma is the most common and aggressive type of primary malignant brain tumour in adults. All glioblastomas are classified as WHO grade 4, indicating rapid growth, extensive invasion into surrounding brain tissue and poor prognosis.
An animal study in June demonstrated that a nano-formulated ivermectin delivered intranasally shrank brain tumours by 70% after just 10 days of treatment.
As Nicolas Hulscher points out, the study’s findings align with ivermectin’s 14 distinct anti-cancer mechanisms.
New Study: Intranasal Nano-Ivermectin Shrinks Brain Tumours by 70% Without Toxicity
By Nicolas Hulscher, as published by Focal Points on 10 October 2025
A groundbreaking preclinical study published in ACS Biomaterials Science & Engineering has revealed that nano-formulated ivermectin delivered intranasally reduced glioblastoma tumour size by 70% – at a dose lower than the approved human antiparasitic dose – all without a trace of toxicity in the brain, blood or lungs.
more:
https://expose-news.com/2025/10/23/ivermectin-shrinks-brain-tumours-by-70/
https://www.youtube.com/watch?v=kVWzT4SYNE4